GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regnum Corp (OTCPK:RGMP) » Definitions » Other Current Receivables

Regnum (Regnum) Other Current Receivables

: $0.00 Mil (As of Mar. 2023)
View and export this data going back to 2019. Start your Free Trial

Regnum's Other Current Receivables for the quarter that ended in Mar. 2023 was $0.00 Mil.


Regnum Other Current Receivables Historical Data

The historical data trend for Regnum's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regnum Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Other Current Receivables
Premium Member Only - - - - -

Regnum Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Other Current Receivables Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Regnum Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.


Regnum Other Current Receivables Related Terms

Thank you for viewing the detailed overview of Regnum's Other Current Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Regnum (Regnum) Business Description

Traded in Other Exchanges
N/A
Address
600 Third Avenue, 19th Floor, New York, NY, USA, 10016
Regnum Corp is focused on developing and commercializing therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a CCR5 antagonist to treat multi-drug resistant HIV infection.

Regnum (Regnum) Headlines

No Headlines